DK3467111T3 - LNCRNAS til terapi og diagnose af hjertehypertrofi - Google Patents

LNCRNAS til terapi og diagnose af hjertehypertrofi Download PDF

Info

Publication number
DK3467111T3
DK3467111T3 DK18201238.5T DK18201238T DK3467111T3 DK 3467111 T3 DK3467111 T3 DK 3467111T3 DK 18201238 T DK18201238 T DK 18201238T DK 3467111 T3 DK3467111 T3 DK 3467111T3
Authority
DK
Denmark
Prior art keywords
lncrnas
diagnosis
therapy
cardiac hypertrophy
hypertrophy
Prior art date
Application number
DK18201238.5T
Other languages
English (en)
Inventor
Thomas Thum
Kumarswamy Regalla
Janika Viereck
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Application granted granted Critical
Publication of DK3467111T3 publication Critical patent/DK3467111T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK18201238.5T 2014-04-22 2015-04-22 LNCRNAS til terapi og diagnose af hjertehypertrofi DK3467111T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14165504 2014-04-22
EP15717502.7A EP3134526B1 (en) 2014-04-22 2015-04-22 Lncrnas for therapy and diagnosis of cardiac hypertrophy

Publications (1)

Publication Number Publication Date
DK3467111T3 true DK3467111T3 (da) 2022-03-14

Family

ID=50630577

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15717502.7T DK3134526T3 (da) 2014-04-22 2015-04-22 LNC-RNA'er til terapi og diagnose af hjertehypertrofi
DK18201238.5T DK3467111T3 (da) 2014-04-22 2015-04-22 LNCRNAS til terapi og diagnose af hjertehypertrofi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15717502.7T DK3134526T3 (da) 2014-04-22 2015-04-22 LNC-RNA'er til terapi og diagnose af hjertehypertrofi

Country Status (11)

Country Link
US (4) US20170183652A1 (da)
EP (2) EP3467111B1 (da)
JP (2) JP6577960B2 (da)
CN (2) CN117224687A (da)
CA (1) CA2945559A1 (da)
DK (2) DK3134526T3 (da)
ES (2) ES2906995T3 (da)
HU (2) HUE041700T2 (da)
PL (2) PL3467111T3 (da)
TR (1) TR201818825T4 (da)
WO (1) WO2015162161A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608907D0 (en) * 2016-05-20 2016-07-06 Ucl Business Plc Means for modulating gene expression
US11667974B2 (en) 2017-06-12 2023-06-06 Firalis Sa Diagnostic, prognostic and therapeutic uses of long noncoding RNAs for pathologies and toxicities inducing heart disorders
CN111032093A (zh) * 2017-06-19 2020-04-17 洛桑大学 控制心肌纤维化和重塑的方法和组合物
CN107326072A (zh) * 2017-06-23 2017-11-07 陈梦麟 Linc00702及其在调控心血管系统中的应用
US12054711B2 (en) 2017-07-14 2024-08-06 City Of Hope Meta-stable oligonucleotides junctions for delivery of therapeutics
EP3665281A4 (en) * 2017-08-10 2021-05-05 City of Hope CONDITIONAL SIRNA AND ITS USE IN THE TREATMENT OF CARDIAC HYERTROPHY
CN113166750A (zh) 2018-08-10 2021-07-23 希望之城 可编程的条件性sirna及其用途
CN110229879B (zh) * 2019-07-01 2022-11-18 青岛大学 一种piRNA-500核苷酸类似物及其反义核苷酸的应用和应用其的产品
CN110878348B (zh) * 2019-11-19 2023-03-28 南京启医科技有限公司 一种具有较高特异性的心衰lnc RNA生物标志物及其检测方法和应用
CN111690673A (zh) * 2020-06-22 2020-09-22 扬州大学 一种lncRNA通过编码小肽促进PGCs形成的验证方法
CN112494651A (zh) * 2020-09-30 2021-03-16 吉林大学 lncRNA H19作为分子靶点在动脉粥样硬化治疗中的应用
CN115698304A (zh) * 2020-10-09 2023-02-03 特纳亚治疗股份有限公司 亲斑蛋白-2基因疗法的方法和组合物
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
AU5819599A (en) 1998-09-11 2000-04-03 Regents Of The University Of California, The Recombinant adenovirus for tissue specific expression in heart
GB0112343D0 (en) 2001-05-21 2001-07-11 Norske Stats Oljeselskap Well treatment
WO2004031359A2 (en) * 2002-10-03 2004-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for regulating expression genes
WO2008104290A1 (en) * 2007-02-27 2008-09-04 Bayer Schering Pharma Aktiengesellschaft H19 as a biomarker for ppara modulators
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants

Also Published As

Publication number Publication date
US20170183652A1 (en) 2017-06-29
US20220315924A1 (en) 2022-10-06
HUE041700T2 (hu) 2019-05-28
TR201818825T4 (tr) 2019-01-21
JP6805304B2 (ja) 2020-12-23
CN117224687A (zh) 2023-12-15
JP6577960B2 (ja) 2019-09-18
JP2017514813A (ja) 2017-06-08
PL3134526T3 (pl) 2019-04-30
DK3134526T3 (da) 2019-02-04
EP3134526B1 (en) 2018-10-31
EP3467111B1 (en) 2021-12-15
ES2706878T3 (es) 2019-04-01
ES2906995T3 (es) 2022-04-21
CA2945559A1 (en) 2015-10-29
JP2020007332A (ja) 2020-01-16
HUE057484T2 (hu) 2022-05-28
US20220348920A1 (en) 2022-11-03
EP3134526A1 (en) 2017-03-01
WO2015162161A1 (en) 2015-10-29
EP3467111A1 (en) 2019-04-10
CN106488777A (zh) 2017-03-08
US20200165604A1 (en) 2020-05-28
US11371043B2 (en) 2022-06-28
PL3467111T3 (pl) 2022-04-11

Similar Documents

Publication Publication Date Title
DK3467111T3 (da) LNCRNAS til terapi og diagnose af hjertehypertrofi
DK3757206T3 (da) Transduktionsfremgangsmåde og cellebehandling
DK2949365T3 (da) Gåtræningsapparat og gåtræningsfremgangsmåde deraf
DK3155024T3 (da) Opholdsstrukturer og relaterede fremgangsmåder
DK3474804T3 (da) Medicinsk forbinding
DE112015002825A5 (de) Nicht-invasive Stoffanalyse
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3142607T3 (da) Hjerteklapprotese
DK3197354T3 (da) Medicinsk anordning
DK3202305T3 (da) Engangsendoskop og system
DK2937422T3 (da) Fremgangsmåde og et kit til ikke-invasiv detektering af patogene genmutationer for fosterdøvhed
DK3218005T3 (da) Glycan-interagerende forbindelser og anvendelsesfremgangsmåder
DK3116911T3 (da) Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3178324T3 (da) Mikrobicid og fremgangsmåde til fremstilling af samme
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3177920T3 (da) På-stedet-diagnosesystem og fremgangsmåde dertil
DK2980351T3 (da) Telemetry system and method of operating the same
DK3123071T3 (da) Koblingsenhed og tilhørende fremgangsmåde
DK3338642T3 (da) Ultralydsdiagnoseanordning og fremgangsmåde til styring af ultralydsdiagnoseanordning
DK3231793T3 (da) Dihydropyromidin-2-on-forbindelser og medicinske anvendelser deraf
DK3166473T3 (da) Oftalmoskoper
DK3474803T3 (da) Medicinsk forbinding
DK3188599T3 (da) Medicinske behandlinger baseret på anamorelin
DK3190964T3 (da) Spirometer